SOPHiA GENETICS Expands AI Collaboration with AstraZeneca to Enhance Breast Cancer Treatment Outcomes

SOPHiA GENETICS, a cloud-native healthcare technology company and global leader in data-driven medicine, has expanded its multi-year collaboration with AstraZeneca to leverage artificial intelligence in improving outcomes for breast cancer patients. The partnership will use SOPHiA GENETICS’s multimodal AI Factories to generate real-world evidence on the effectiveness, value, and impact of breast cancer therapies. It also aims to develop a customized AI-powered predictive model to help personalize treatment decisions and optimize patient outcomes. The AI Factories are built on advanced computing protocols and trained on one of the most diverse multimodal healthcare datasets available. They integrate genomics, medical imaging, and clinical data to deliver powerful predictive insights into patient prognosis and treatment response. AstraZeneca will use these tools to analyze complex, real-world data across Europe and North America, helping to identify key factors influencing therapy success, fill critical knowledge gaps, and support more informed clinical decisions. Ross Muken, President of SOPHiA GENETICS, highlighted the importance of secure, scalable, and compliant AI applications in healthcare. “This collaboration underscores the growing demand for trusted, federated analytics that harness data and AI to drive better patient outcomes,” he said. “Our platform is designed to handle complex healthcare data environments, and this partnership reinforces our shared mission to advance global health through innovation.” Jorge Reis-Filho, Chief AI and Data Scientist at AstraZeneca, emphasized the strategic role of AI in oncology. “Our AI strategy focuses on deploying cutting-edge solutions across clinical development,” he said. “By integrating multimodal data—including our own and data generated through this collaboration—we are gaining a deeper, more holistic understanding of disease biology and biomarkers, enabling us to tailor more effective treatments for patients.” The expanded collaboration strengthens SOPHiA GENETICS’ position as a trusted technology partner in advancing precision medicine. It also highlights the company’s commitment to using federated data analytics and AI to improve healthcare outcomes worldwide. The SOPHiA DDM™ Platform, which powers the AI Factories, is already used by a global network of hospitals, laboratories, and biopharmaceutical institutions to deliver real-time, actionable insights in cancer and rare disease care. For more information, visit SOPhiAGENETICS.COM or follow the company on LinkedIn. Note: SOPHiA GENETICS products are for Research Use Only and not for diagnostic use unless otherwise specified. Availability and regulatory status vary by country. Contact [email protected] for product details in your region. Forward-looking statements in this release are based on current expectations and involve risks that could cause actual results to differ materially. These include factors detailed in the company’s SEC filings. SOPHiA GENETICS disclaims any obligation to update these statements except as required by law.